{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"1.8","value":"1.7"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"6.2","value":"3.1"},{"groupId":"OG002","lowerLimit":"1.5","upperLimit":"1.8","value":"1.7"},{"groupId":"OG003","lowerLimit":"1.7","upperLimit":"2.9","value":"1.8"},{"groupId":"OG004","lowerLimit":"1.4","upperLimit":"2.1","value":"1.8"},{"groupId":"OG005","lowerLimit":"3.5","upperLimit":"10.7","value":"5.5"},{"groupId":"OG006","lowerLimit":"3.5","upperLimit":"13.9","value":"4.5"},{"groupId":"OG007","lowerLimit":"1.4","upperLimit":"3.6","value":"1.8"},{"groupId":"OG008","lowerLimit":"1.8","upperLimit":"3.5","value":"1.9"},{"groupId":"OG009","lowerLimit":"1.6","upperLimit":"2.7","value":"1.8"},{"groupId":"OG010","lowerLimit":"1.6","upperLimit":"3.2","value":"1.8"},{"groupId":"OG011","lowerLimit":"1.4","upperLimit":"3.7","value":"2.5"},{"groupId":"OG012","lowerLimit":"1.7","upperLimit":"5.8","value":"1.8"},{"groupId":"OG013","lowerLimit":"3.5","upperLimit":"8.2","value":"5.5"},{"groupId":"OG014","lowerLimit":"2.2","upperLimit":"14.4","value":"8.2"},{"groupId":"OG015","lowerLimit":"1.8","upperLimit":"5.1","value":"3.6"},{"groupId":"OG016","lowerLimit":"3.5","upperLimit":"13.4","value":"6.4"},{"groupId":"OG017","lowerLimit":"1.9","upperLimit":"8.1","value":"2.8"},{"groupId":"OG018","lowerLimit":"1.7","upperLimit":"5.3","value":"2.0"},{"groupId":"OG019","lowerLimit":"1.7","upperLimit":"6.5","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"26"},{"groupId":"OG009","value":"23"},{"groupId":"OG010","value":"24"},{"groupId":"OG011","value":"18"},{"groupId":"OG012","value":"23"},{"groupId":"OG013","value":"25"},{"groupId":"OG014","value":"22"},{"groupId":"OG015","value":"26"},{"groupId":"OG016","value":"27"},{"groupId":"OG017","value":"25"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"23"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of allocation to the date of the first documentation of disease progression, as determined by investigator per modified RECIST 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \\[mm\\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with colon or rectal adenocarcinoma.","id":"OG000","title":"Cohort A1: Colon or Rectal Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with anal canal squamous cell carcinoma.","id":"OG001","title":"Cohort A2: Anal Canal Squamous Cell Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with pancreas adenocarcinoma.","id":"OG002","title":"Cohort A3: Pancreas Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with esophageal squamous cell carcinoma or adenocarcinoma (including gastroesophageal (GE) junction).","id":"OG003","title":"Cohort A4: Esophageal Squamous Cell Carcinoma or Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with biliary tract adenocarcinoma (gallbladder and biliary tree, but excluding ampulla of vater cancers).","id":"OG004","title":"Cohort A5: Biliary Tract Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with carcinoid tumors.","id":"OG005","title":"Cohort A6: Carcinoid Tumors"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with neuroendocrine carcinomas (well or moderately differentiated pancreatic neuroendocrine tumor).","id":"OG006","title":"Cohort A7: Neuroendocrine Carcinomas"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with ER positive HER2 negative breast cancer.","id":"OG007","title":"Cohort B1: ER Positive HER2 Negative Breast Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with ovarian epithelial, fallopian tube or primary peritoneal carcinoma.","id":"OG008","title":"Cohort B2: Ovarian Epithelial, Fallopian Tube or Primary Peritoneal Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with endometrial carcinoma","id":"OG009","title":"Cohort B3: Endometrial Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with cervical squamous cell cancer.","id":"OG010","title":"Cohort B4: Cervical Squamous Cell Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with vulvar squamous cell carcinoma.","id":"OG011","title":"Cohort B5: Vulvar Squamous Cell Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with small cell lung cancer.","id":"OG012","title":"Cohort C1: Small Cell Lung Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with mesothelioma (malignant pleural mesothelioma).","id":"OG013","title":"Cohort C2: Mesothelioma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with thyroid cancer (papillary or follicular subtype).","id":"OG014","title":"Cohort D1: Thyroid Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with salivary gland carcinoma.","id":"OG015","title":"Cohort D2: Salivary Gland Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with nasopharyngeal carcinoma.","id":"OG016","title":"Cohort D3: Nasopharyngeal Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with glioblastoma multiforme.","id":"OG017","title":"Cohort E1: Glioblastoma Multiforme"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with leiomyosarcoma.","id":"OG018","title":"Cohort E2: Leiomyosarcoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with prostate adenocarcinoma.","id":"OG019","title":"Cohort E3: Prostate Adenocarcinoma"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received at least 1 dose of study treatment, had a baseline scan with measurable disease per modified RECIST 1.1 and had the intended indication. Per protocol, participants were analyzed according to disease type.","reportingStatus":"POSTED","timeFrame":"Up to approximately 86 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}